Nano Pharmaceuticals
Market Cap
₹63 ₹63.00 Cr.
P/E
6.99
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.03
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
22.10 %
Institutions
Institutions
-
Market cap
Market cap
63.00 Cr
No. of Shareholders
No. of Shareholders
1,060
OPM (%)
OPM (%)
17.40 %
PE
PE
6.99
Prom Holding
Prom Holding
44.99 %
ROCE (%)
ROCE (%)
22.46
ROE (%)
ROE (%)
16.94
Sales
Sales
73.13 Cr
  • Shelter Pharma
  • Onyx Biotec
  • Phaarmasia
Last updated on 25 Sep 2026
  • Shelter Pharma makes herbal Ayurvedic medicines for people and animals, with 300+ formulations.
  • It sells across India through stockists and pharmacies on doctor prescriptions, and exports to 10+ countries at about 9% of revenue.
  • Human and animal medicines earn similar margins. Key products are the kidney-stone drink Lemonade Barley Water, the laxative Sherolax and the gas tablet Gasoshel.
  • It carries a 60-year Ayurvedic brand. It is GMP and ISO 9001:2015 certified with five products approved for the Middle East.
  • It is building a second plant at Himmatnagar. It is shifting toward premium nutraceuticals and wider sales in India and abroad.
  • Cash lags profit as stock and advances absorb cash. Working cycle was 234 days and operating cash was negative in FY26.
  • It is digesting a sales-team build. Management guides 40% growth for FY27-28 toward Rs 200Cr by 2030 with margin above 20% going forward.
  • Related-party advances remain large and drew a compliance breach in FY26. Disputed tax of Rs 3.64Cr is still pending.
  • Residual warrant conversions anytime to ~Feb 2027
    remaining warrants convert at Rs 42.25 per share for working capital. It adds cash but lifts share count beyond 1.66Cr shares.
  • First test of growth and margin guides ~mid-Nov 2026
    H1 print shows if 40% growth and margin above 20% are on track. It also shows cash and export run-rate.
  • Second plant at Himmatnagar end-2027
    Rs 12-15Cr capex adds headroom beyond the Rs 100Cr cap of the existing plant. Funding is planned from internal accruals.
  • Related-party advance compliance No timeline
    disclosures show if advances stay within the Rs 25Cr cap per party. It settles if the FY26 breach repeats.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
23
52W Range
High
47
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

3 Neutral

Neutral for this company

3 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Shelter Pharma Ltd. Business

Shelter Pharma Limited specializes in manufacturing herbal products for Human Pharma and Veterinary segments in Gujarat. They offer a range of OTC and Ethical pharma products developed through in-house R&D and Ayurvedic expertise.

Shelter Pharma major competitors are Cian Healthcare, Shanmuga Hospital, Phaarmasia, Rekvina Laboratories, Onyx Biotec, Source Natural Foods, ANG Lifesciences.
Market Cap of Shelter Pharma is ₹61 Crs.
While the median market cap of its peers are ₹61 Crs.

Shelter Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Shelter Pharma is 6.13 and is ranked 4 out of its 8 competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation Jun
Conference Call Jun
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material